These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12723978)

  • 21. Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.
    Hu C; Wong FS; Wen L
    Clin Exp Immunol; 2009 Aug; 157(2):181-90. PubMed ID: 19604257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
    Perosa F; Prete M; Racanelli V; Dammacco F
    J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B cell targeted therapy in autoimmunity.
    Blank M; Shoenfeld Y
    J Autoimmun; 2007; 28(2-3):62-8. PubMed ID: 17391915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New therapeutic approaches to autoimmune diseases].
    Amoura Z; Piette JC
    Presse Med; 2006 Apr; 35(4 Pt 2):709-13. PubMed ID: 16614619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B cell-ablative therapy: where are we now?
    Bordron A; Mankaï A; Bendaoud B; Saraux A; Devauchelle V; Ghedira I; Jamin C; Pers JC; Berthou C; Youinou P
    Int J Immunopathol Pharmacol; 2007; 20(4):655-9. PubMed ID: 18179738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
    Edwards JC; Leandro MJ; Cambridge G
    Curr Dir Autoimmun; 2005; 8():175-92. PubMed ID: 15564721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The humoral response in rheumatoid arthritis and the effect of B-cell depleting therapy].
    Thurlings RM; Vos K; Gerlag DM; Tak PP
    Ned Tijdschr Geneeskd; 2006 Jul; 150(30):1657-61. PubMed ID: 16922350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.
    Edwards JC; Leandro MJ; Cambridge G
    Rheum Dis Clin North Am; 2004 May; 30(2):393-403, viii. PubMed ID: 15172048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B cells in health and disease.
    Carter RH
    Mayo Clin Proc; 2006 Mar; 81(3):377-84. PubMed ID: 16529141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm.
    Moreland LW; Heck LW; Sullivan W; Pratt PW; Koopman WJ
    Am J Med Sci; 1993 Jan; 305(1):40-51. PubMed ID: 8416681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
    Liossis SN; Sfikakis PP
    Clin Immunol; 2008 Jun; 127(3):280-5. PubMed ID: 18337174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy in autoimmune diseases.
    Fong KY
    Ann Acad Med Singap; 2002 Nov; 31(6):702-6. PubMed ID: 12520821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.
    Leandro MJ; de la Torre I
    Clin Exp Immunol; 2009 Aug; 157(2):191-7. PubMed ID: 19604258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis.
    Brühl H; Cihak J; Talke Y; Rodriguez Gomez M; Hermann F; Goebel N; Renner K; Plachý J; Stangassinger M; Aschermann S; Nimmerjahn F; Mack M
    Eur J Immunol; 2015 Mar; 45(3):705-15. PubMed ID: 25471597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapeutic Targeting in Autoimmune Diseases.
    Janikashvili N; Samson M; Magen E; Chikovani T
    Mediators Inflamm; 2016; 2016():1432702. PubMed ID: 28074079
    [No Abstract]   [Full Text] [Related]  

  • 36. B Cell Modulation Strategies in Autoimmune Diseases: New Concepts.
    Musette P; Bouaziz JD
    Front Immunol; 2018; 9():622. PubMed ID: 29706952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depletion of B cells in murine lupus: efficacy and resistance.
    Ahuja A; Shupe J; Dunn R; Kashgarian M; Kehry MR; Shlomchik MJ
    J Immunol; 2007 Sep; 179(5):3351-61. PubMed ID: 17709552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice.
    Dörner T; Burmester GR
    Rheumatology (Oxford); 2007 Apr; 46(4):563-4. PubMed ID: 17337751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.